Pancopride is a dopamine D2 receptor antagonist and a 5-HT3 receptor antagonist. It is being studied for its potential to treat gastrointestinal disorders such as gastroparesis and irritable bowel syndrome. Pancopride is a synthetic compound and is not available commercially. It is currently in clinical trials. Research into pancopride focuses on its mechanism of action, therapeutic efficacy, and safety. It is of interest because it may provide a novel treatment option for patients with gastrointestinal disorders who do not respond well to existing therapies.'
pancopride: structure given in first source; a selective 5-HT3 receptor antagonist; effective against anticancer drug-evoked emesis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71342 |
| CHEMBL ID | 2107188 |
| CHEBI ID | 177586 |
| SCHEMBL ID | 120427 |
| MeSH ID | M0210085 |
| Synonym |
|---|
| pancopride |
| CHEBI:177586 |
| 4-amino-n-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-(cyclopropylmethoxy)benzamide |
| D05348 |
| 121650-80-4 |
| pancopride (usan/inn) |
| n-(1-azabicyclo[2.2.2]oct-3-yl)-2-cyclopropylmethoxy-4-amino-5-chlorobenzamide |
| DBQMQBCSKXTCIJ-UHFFFAOYSA-N |
| las-30451 |
| CHEMBL2107188 |
| las 30451 |
| SCHEMBL120427 |
| CS-6681 |
| HY-19684 |
| 4-amino-n-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-(cyclopropylmethoxy)benzene-1-carboximidic acid |
| DTXSID70923732 |
| 121243-20-7 |
| 4-amino-5-chloro-2-(cyclopropylmethoxy)-n-(quinuclidin-3-yl)benzamide |
| AKOS040742365 |
Pancopride (PNC) is a new 5HT3 receptor antagonist. It has demonstrated complete protection from nausea and vomiting in 25-73% of patients treated with highly emetogenic chemotherapy.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pancopride (PNC) is a new 5HT3 receptor antagonist which has demonstrated complete protection from nausea and vomiting in 25-73% of patients treated with highly emetogenic chemotherapy. " | ( Prevention of highly emetogenic chemotherapy-induced vomiting: a double blind, randomized crossover study to compare pancopride (LAS 30451) and pancopride plus dexamethasone. Aranda, E; Barneto, IC; Garcia, A; Gonzalez, R; Perez, A; Rubio, MJ, ) | 1.78 |
The aim of this study was to assess the pharmacokinetic profile of pancopride after repeated oral dose administration. Pharmacokinetic parameters for the 24 h after dosing were derived from plasma and urine pancreatopride levels.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters for the 24 h after dosing were derived from plasma and urine pancopride levels, determined using a capillary gas chromatography-mass spectrometry method." | ( Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers. Dewland, P; Martinez-Tobed, A; Pérez Campos, A, 1995) | 0.77 |
| "The aim of this study was to assess the pharmacokinetic profile of pancopride after repeated oral dose administration of 20 mg pancopride in tablet form once a day for 5 d in 12 healthy male volunteers." | ( Repeated dose pharmacokinetics of pancopride in human volunteers. Costa, J; Martínez-Tobed, A; Pérez-Campos, A; Salva, P, 1994) | 0.8 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The studies consisted of two rising dose tolerance and kinetic studies with placebo control, each involving 14 volunteers, and an absolute bioavailability study involving 12 volunteers." | ( Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers. Dewland, P; Martinez-Tobed, A; Pérez Campos, A, 1995) | 0.55 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic parameters for the 24 h after dosing were derived from plasma and urine pancopride levels, determined using a capillary gas chromatography-mass spectrometry method." | ( Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers. Dewland, P; Martinez-Tobed, A; Pérez Campos, A, 1995) | 0.77 |
| " The area under the concentration-time curve during the dosing interval (AUCss tau) was 995 +/- 389 ng h mL-1." | ( Repeated dose pharmacokinetics of pancopride in human volunteers. Costa, J; Martínez-Tobed, A; Pérez-Campos, A; Salva, P, 1994) | 0.57 |
| Class | Description |
|---|---|
| benzamides | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (57.14%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (28.57%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||